<DOC>
	<DOCNO>NCT01457495</DOCNO>
	<brief_summary>This study assess immunogenicity GlaxoSmithKline ( GSK ) Biologicals ' ( formerly SmithKline Beecham Biologicals ' ) DTPa-HBV-IPV/Hib ( Infanrix hexa™ ) vaccine compare separate administration DTPa-HBV-IPV ( Infanrix™ penta ) Hib ( Hiberix™ ) vaccine administer 3 5 month age .</brief_summary>
	<brief_title>Immunogenicity Safety DTPa-HBV-IPV/Hib Compared DTPa-IPV/Hib HBV Administered Concomitantly</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Pentetic Acid</mesh_term>
	<mesh_term>Edetic Acid</mesh_term>
	<criteria>A male female 12 16 week age time first vaccination . Free obvious health problem establish medical history clinical examination enter study . Written inform consent obtain parent guardian subject advise risk benefit study language clearly understood , performance study procedure . Use investigational nonregistered drug vaccine study vaccine ( ) study period within 30 day precede first dose study vaccine . Administration chronic immunosuppressant immunemodifying drug study period . Administration vaccine foreseen study protocol period start one month dose end one month dose . Previous vaccination diphtheria , tetanus , pertussis , hepatitis B , polio and/or Hib diseases . History of/or intercurrent diphtheria , tetanus , pertussis , hepatitis B , polio and/or Hib disease . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . History allergic disease reaction likely exacerbated component vaccine , include allergic reaction neomycin polymyxin B . Major congenital defect serious chronic illness . Progressive neurological disorder . Administration immunoglobulins and/or blood product since birth study period . Acute febrile illness time plan vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>12 Weeks</minimum_age>
	<maximum_age>16 Weeks</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Infants</keyword>
	<keyword>combine vaccine</keyword>
	<keyword>DTPa-HBV-IPV/Hib</keyword>
	<keyword>DTPa-IPV/Hib</keyword>
	<keyword>safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>HBV</keyword>
</DOC>